News Otsuka has high hopes for its 'drug creation engine' acquisi... Otsuka is paying $430 million for a US clinical-stage biotech company it hopes will act as a ‘drug creation engine’ to accelerate its research into kidney diseases.
News EU approves AZ's potential blockbuster hyperkalaemia drug After manufacturing issues, AstraZeneca hopes for FDA nod soon.
News AZ signs kidney drug deal with Ionis for up to $330m Deal is result of six-year collaboration with AZ
News Alexion drug fails in kidney transplant trial Soliris fails when used to treat post-transplant complications.
News GSK begins phase 3 trials of kidney drug Daprodustat is potential treatment for anaemia with CKD.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
